May 24, 2017
No statistically significant connections between piperacillin and adverse events, such as seizures and rashes, in infants were observed in a study of drug exposure outcomes from a national electronic health record database.
“Evaluating drug safety in infants is challenging for several reasons. Performing trials with an adequate number of infants to assess drug safety requires considerable time and resources,” Sara Salerno, PharmD, from the UNC Eshelman School of Pharmacy, and colleagues wrote. “Using electronic health record data from national databases can be a suitable approach to evaluate drug safety in infants since it can overcome many of these limitations of traditional clinical trials.”